QPS IS SUPPORTING THE FIGHT
We are currently in the midst of the greatest global health crisis in decades: the COVID-19 pandemic. As this novel coronavirus affects communities around the world, there is an increasingly urgent demand for available and accurate COVID-19 testing services, effective COVID-19 drug therapies, and a COVID-19 vaccine. With its proven quality standards, technical expertise, turnkey laboratories, and decades of experience, QPS is well prepared to support your novel coronavirus or COVID-19-related project.
QPS IS OPEN FOR BUSINESS
QPS remains open and fully operational, supporting preclinical and clinical novel coronavirus drug therapy and vaccine development, as well as providing a range of testing capabilities. With multiple phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to safely fast-track first-in-man and Phase I/II studies for compounds in development to combat the novel coronavirus.
QPS' Toxicology Center of Excellence, QPS Taiwan (CTPS), is actively supporting multiple sponsors to assess the safety of their vaccine candidates. They are ready to take on more of this work.
Our Bioanalysis teams are analyzing clinical trial samples that are known to be contaminated, or could be contaminated, with the novel coronavirus at the access-restricted bioanalysis labs on our campuses in Newark, Delaware, USA, The Netherlands and India. They are also providing preclinical and clinical bioanalytical support towards multiple COVID-19 vaccine candidates.
With multiple phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to safely fast-track first-in-man and Phase I/II studies for compounds in development to combat the novel coronavirus.
CONTACT QPS TODAY TO DISCUSS YOUR CORONAVIRUS RELATED PROJECT
QPS Clinical Study Start Up Guide
Global QPS clinical study sites are up and running, taking all appropriate precautions. Read all about our plans in this brochure.
QPS COVID-19 Testing Infographic
QPS LLC has an FDA Emergency Use Authorized (EUA) COVID-19 molecular assay for detection of SARS-CoV-2, available as a private, contract service.
QPS Testing and Clinical Study FAQ
If the Study Start Up Guide does not answer all of your questions, please review these Frequently Asked Questions.
QPS Overview of Available Tests
QPS is supporting sponsored clinical trials using our subject recruitment services and clinics distributed globally.
QPS COVID-19 Related Blog Posts
At QPS we have been using our Blog to providing insights into the novel coronavirus pandemic since it started in early 2020.
QPS Letter to Sponsors
The global COVID-19 Pandemic affects every American and every American business. We all need to get back to work.
With multiple Phase I clinical research sites around the world, and over 600 Phase I beds, QPS is also well positioned to fast-track first-in-man and Phase I/II safety studies for compounds in development to combat the novel coronavirus. Furthermore, as a full service CRO QPS has all clinical research capabilities as well as efficient access to specialized sites and experienced investigators with the capability to run COVID-19 patient trials in EU, US and Asia.
QPS has decades of experience assisting pharmaceutical companies slow the progress of viral outbreaks, and we are committed to supporting the life sciences community in fighting COVID-19. Due to the catastrophic reach of this pandemic, a scientific breakthrough is direly needed, and our team is ready to move your clinical trials, serological assays, and vaccine and drug development programs toward a regulatory submission.
Please use the form below to submit your request for preclinical or clinical drug development and testing services related to the novel coronavirus or COVID-19.
Contact Us Today!
QPS is ready to support your novel coronavirus or COVID-19-related project.
More Information About COVID-19
The spread of COVID-19 is impacting every facet of the pharmaceutical industry, including planned and ongoing clinical trials. Recognizing that the coronavirus presents challenges to protocol-specified procedures, the Food and Drug Administration (FDA) has published guidelines regarding the conduct of clinical trials during this unprecedented time. To learn more about these guidelines, please visit our page Clinical Trials: Coronavirus Impact and FDA Guidelines.
src in: https://www.youtube.com/embed/5hu7_xIsCRg?feature=oembed&wmode=opaque
src gen: https://www.youtube.com/embed/5hu7_xIsCRgActual comparison
src in: https://www.youtube.com/embed/5hu7_xIsCRg?wmode=opaque
src gen: https://www.youtube.com/embed/5hu7_xIsCRg
Today, the FDA issued a new video resource explaining the different categories of tests in the fight against COVID-19: diagnostic tests and antibody tests. As the video explains, diagnostic tests can tell if the tested person currently is infected. Antibody or serology tests detect if the person’s blood contains antibodies to coronavirus. The body produces antibodies when one becomes infected by the virus, and they help the immune system fight off the infection. If an antibody test finds antibodies in the blood, it likely means the person has been previously infected with the virus. Antibody tests do not detect whether a person is currently infected and should not be used to diagnose a current COVID-19 infection. The results from antibody tests can help us better understand questions about exposure to COVID-19.